"A single intravenous (IV) dose of the HIV entry inhibitor PRO 140reduced virus by nearly 100-fold for up to 10 days in a small phase IIa study, according to a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco and reported by the National AIDS Treatment Advocacy Project (NATAP).
"PRO 140 is a monoclonal antibody. Monoclonal antibodies are artificially created antibodies that can attach to viruses, bacteria or even human cells. Pro 140 attaches to a CD4 cell receptor called CCR5, which HIV uses to enter and infect CD4 cells."
Read more in POZ, September 15, 2009.
0 comments:
Post a Comment